Menu
Not yet recruiting NCT07396922

Assessment of Safety and Effectiveness of Spatial StimelMD (SSMD) in Subjects With Upper Limb Neuromotor Impairments

No phase Interventional Stroke TBI Spinal Cord Injury Peripheral Nerve Damage

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: SSMD, Functional Electrical Stimulation (FES).
Who it may be relevant to
Registry conditions: Stroke, TBI, Spinal Cord Injury, Peripheral Nerve Damage. Basic parameters: 18 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Poland
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Randomized, Controlled Study to Evaluate the Efficacy and Safety of the SSMD in Neuromotor Rehabilitation

Overview

This study will evaluate the safety and performance of the Spatial StimeMD (SSMD) medical device in people with multiple sclerosis (MS). The SSMD device is intended to support patients through a non-invasive stimulation program. The study will assess changes in MS-related symptoms and physical function using clinical assessments and patient-reported outcomes.

Detailed description

This is a clinical investigation of the Spatial StimeMD (SSMD) medical device in participants diagnosed with multiple sclerosis (MS). The purpose of the study is to evaluate the safety and performance of the device in a controlled clinical setting. Participants will be followed according to the study schedule and will undergo assessments of MS symptoms, physical function, and other relevant clinical outcomes. Safety will be assessed through monitoring of adverse events and other safety parameters throughout the study. Study data will be collected and reviewed according to the protocol, including verification against source documentation as required.

Interventions

  • Device SSMD
    SSMD device-based therapy delivered in addition to conventional therapy. Participants receive 18 sessions, 30 minutes each, administered 6 sessions per week over 3 weeks.
  • Device Functional Electrical Stimulation (FES)
    Functional electrical stimulation (FES) delivered in addition to conventional therapy. Participants receive 18 sessions, 30 minutes each, administered 6 sessions per week over 3 weeks.

Primary outcome measures

  • Change in Fugl-Meyer Upper Extremity (FMA-UE) motor score [Time frame: Baseline to post-treatment (end of treatment, 3 weeks)]
Secondary outcome measures (3)
  • change in Movement range and movement quality (SSMD assessment mode) [Time frame: Baseline to post-treatment (end of treatment, Week 3)]
  • Change in Functional Independence Measure (FIM) score [Time frame: Baseline to post-treatment (end of treatment, Week 3)]
  • Change in EMG signal strength (threshold) [Time frame: Baseline to post-treatment (end of treatment, Week 3)]

Eligibility criteria

Inclusion criteria

  • Adult men and women aged 18-80 years.
  • Clinically confirmed diagnosis of stroke, TBI, spinal cord injury, or peripheral nerve injury within the past 24 months.
  • Presence of moderate to severe neuromotor impairment in at least one limb, as evidenced by medical evaluation and a score <35 on the Fugl-Meyer Upper Extremity motor subscale (FMA-UE).
  • Capacity and willingness to provide informed consent, indicating understanding of the study purpose, procedures, and potential risks and benefits.
  • Subject is able to adhere to the study schedule and cognitively capable to perform the treatment.
  • Stable medical condition without ongoing acute complications that could interfere with participation.

Exclusion criteria

  • Presence of contraindications to electrical stimulation (ES), including implanted electronic medical devices (e.g., Cardiac demand pacemakers, Implantable pacemakers, Implantable cardioverter defibrillators, Implantable neurostimulators, Body-worn devices such as insulin pumps) or conditions that may be exacerbated by electrical stimulation (e.g., uncontrolled epilepsy).
  • Individuals with medical conditions, which are prone to seizures or motion sensitivity, at the investigator's discretion.
  • Individuals with light sensitivity, as the AR component may involve visual stimuli that could cause discomfort or adverse reactions in these patients.
  • Individuals with acute physical conditions or injuries that could interfere with the proper placement of the electrodes or safe use of the device.
  • Presence of spinal shock or unresolved acute spinal cord dysfunction, characterized by complete loss of reflexes, flaccid paralysis, or autonomic instability.
  • Current participation in other clinical trials that could confound the study results.
  • Severe cognitive impairment that precludes the ability to provide informed consent or reliably adhere to the study protocol, as determined by cognitive screening and clinical judgment.
  • Women who are pregnant, nursing, or who plan to become pregnant while in the trial.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

Poland · 1 center
  • Polsko-Amerykańskie Kliniki Serca SA, Uzdrowisko Ustroń — Ustroń

Identifiers

NCT: NCT07396922 · CP-SSMD-02

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗